a pap smear utilizing the bethesda system done by manual
LINK 1 ENTER SITE >>> Download PDF
LINK 2 ENTER SITE >>> Download PDF
File Name:a pap smear utilizing the bethesda system done by manual.pdf
Size: 4872 KB
Type: PDF, ePub, eBook
Category: Book
Uploaded: 27 May 2019, 18:55 PM
Rating: 4.6/5 from 720 votes.
Status: AVAILABLE
Last checked: 8 Minutes ago!
In order to read or download a pap smear utilizing the bethesda system done by manual ebook, you need to create a FREE account.
eBook includes PDF, ePub and Kindle version
✔ Register a free 1 month Trial Account.
✔ Download as many books as you like (Personal use)
✔ Cancel the membership at any time if not satisfied.
✔ Join Over 80000 Happy Readers
a pap smear utilizing the bethesda system done by manualIt looks like your browser needs updating. For the best experience on Quizlet, please update your browser. Learn More MICROSCOPIC DESCRIPTION: Sections of prostate show both glandular and stromal nodular hyperplasia. Focally, glands show variable cystic dilatation, basal cell hyperplasia and there are focal mild acute and chronic inflammatory infiltrates. A few fragments show prostatic urethra with benign urothetium and mild chronic inflammatory infiltrates. There is a focus of infiltrative single, separate, loosely packed, small uniform low grade malignant glands with slightly enlarged hyper chromatic nuclei with nucleoli, with some cautery artifact, involving less than 1 of the specimen. DIAGNOSIS: Transurethral resection prostate: Focal adenocarcinoma, primary Gleason grade 2 involving less that 1 of the specimen and adenomyomatous hyperplasia with mild acute and chronic inflammation. The largest piece measures 0.3 0.3 cm and the smallest piece measures 0.2 0.1 cm in greatest dimensions. MICROSCOPIC DESCRIPTION: 1 microscopic slide examined.What type of nurse can administer anesthesia under the direction of an anesthesiologist. Certified Registered Nurse Anesthetists(CRNA) Concurrent modifiers are used to describe: indicate how many cases an anesthesiologist was performing or supervising at one time. In the Anesthesia section of the CPT manual, the codes are usually divided first by which of the following.HCPCS modifiers If anesthesia was provided to a patient who is not expected to survive without the surgical procedure being performed, which physical status modifier would be appended to the anesthesia code.False Local anesthesia is a type of anesthesia that provides a decreased level of consciousness. False Only one CPT procedure code may be represented by one anesthesia code. True Anesthesia services include postoperative visits to the patient by the anesthesiologist.http://www.radicalsport.com.br/datamont/userfiles/dgs-1008tl-manual.xml
- Tags:
- a pap smear utilizing the bethesda system done by manual, a pap smear utilizing the bethesda system done by manual pdf, a pap smear utilizing the bethesda system done by manuals, a pap smear utilizing the bethesda system done by manual download, a pap smear utilizing the bethesda system done by manual free.
True Qualifying anesthesia circumstances are adjunct codes and are used when the administration of the anesthesia is more difficult. The anesthesiologist begins preparing the patient for anesthesia When time is calculated for anesthesia services, the time begins when: CRNA What type of nurse can administer anesthesia under the direction of an anesthesiologist.CPT code: THIS SET IS OFTEN SAVED IN THE SAME FOLDER AS. MIBIE STEP BY STEP CHAP 30 STUDY GUIDE WEEK 03 35 terms dream33611 Coding 120 terms auburn1025 Outpatient Coding Chapter 22 10 terms melanie6617 Outpatient Chapter 26 12 terms melanie6617 YOU MIGHT ALSO LIKE. Virginia Health System Laboratories Cytopathology October 2010 Its primary purpose is to identifyThe Pap test is a highly complexLike all laboratoryA Pap test is best viewed as aThe cervix and the area adjacentThe ecto- andThe material obtained can beThinprep Pap test vials and Item ID 92190 bag of 25 collector setsCervex broom collectors and conventional PapThe preferredIntercourseSome physicianIn addition,Slowly rotate ? or ?Swirl the brushDiscard the brush. Use a diamond point pencil to label plain glassFederal regulations require thatLaboratory personnel cannotReview and followDo not smear, but allow theScrape the ectocervix with thePerform thisImmediately spray fix by thoroughly soaking the cellular sample whileImmediately sprayAllow spray fixative to evaporate. Remove the brush and roll it across theRubbing or scraping the brushImmediately spray fix by thoroughly soaking the cellular sample whileAllow spray fixative to evaporate. Consultation with clinicians in the Department of Obstetrics and. Gynecology who are familiar with such procedures is recommended priorA resident may beExplanations for HPVCytopathology Request form, computer generated registration labels areThis information is important forCase numbersNOT replace written descriptions of previous findings.http://www.meress.sk/userfiles/dgs-1216t-manual.xml Do not use the LMP date line for thisMissing vital dataBethesda System for reporting the cytologic interpretations ofA description of this system is givenInpatient andUnder this system theSome minor changes andInfectious organisms are reported directly with the “Negative”The intent, content, and scope of TBS remain intact. Interpretation: No conditions exist (e.g.The cellular material remains sufficient to render an interpretationRendering a cytologicIn this category the statement of adequacy or lack thereof, becomes theAll identifiable limiting factors forNo cytologicIn addition, all specimens inIf the two cytotechnologistsIf the two reviewers doThe descriptive terminologyTBS limits theWhenever possible, the use ofThe results will provide a briefRefer to the section on HPV testing pagesMalignancy Negative interpretation): Candida species Evaluation Standards of AdequacyClin Path 1974;61:285-286. Papanicolaou Smear. JAMA 1989;262:1672-1679. PG, Elias A, van der Graaf Y, et al. Relationships Between the. Diagnosis of Epithelial Abnormalities and the Composition of Cervical. Smears. Acta Cytol 1985;29:323-328. Diagnoses - Report of the 1991 Bethesda Workshop. JAMA Cytol 1993;37:115-124. DNA with genotyping on the ThinPrep Pap Test. This test isThe Roche CobasHPV 16 and HPV 18 from the 12 other HPV high-risk types. HPVBecause of storageIn addition,Orders Screening (means the Primary Screening FDA algorithm) Clinicians will not need toRefer immediately for HPV testing once the Pap test has been run. Perform HPV testing only if the cytologic interpretation is ASCUS orRequest forms HPV Test Orders Interpretation: Perform HPV testing even if the interpretationSuch a request shouldClients without access to EPICMelinda Poulter, at PIC 3677 with questions. Dr. Mark Stoler isZhang, G., Behrens, C., Wright, T.L., Evaluation of HPV-16 and. Negative Results. AM J Clin Patholo. The human papillomavirus (HPV) test and the Pap test examine cells from a woman’s cervix. The Pap test looks at the cells to see if they are cancerous. In the HPV test, the cells are analyzed for HPV infection. Previously, the USPSTF had recommended use of both the HPV test and the Pap test every five years, for women in the age range 30 to 65. According to the 2018 USPSTF guidelines: Physicians need to know which codes to report for administering a pap smear at a visit as well as the payer reimbursement guidelines for this service.List separately in addition to code(s) or other technical and interpretive services. In this case, CMS instructs that both procedure codes should be reported as separate line items on the claim. HCPCS codes should be used to report screening Pap tests, for the physician interpretation of the screening Pap test, and to report when the physician obtains and prepares the specimen, conveys the test, and sends the specimen to a laboratory. Here are some points to note with regard to Q0091:In other words, Q0091 should not be used when the Pap smear is done for diagnostic purposes. Website Design by MedResponsive. Pap tests are used to identify pre-cancerous or cancerous tissues present on the cervix. Screening for HPV aids in identifying individuals at higher risk for developing cervical cancer. Note: This document addresses the use of cervical cancer screening in the general population. It does not address the use of cervical cancer screening technologies or procedures for the work-up or surveillance of either individuals with known precancerous lesions or a known history of cervical cancer. Not Medically Necessary: Cervical cancer screening with cytology for is considered not medically necessary for all other indications including, but not limited to when the criteria above have not been met. Coding The following codes for treatments and procedures applicable to this guideline are included below for informational purposes.http://gulzarihacegandergisi.com/images/a-manual.pdf Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member. Cervical cancer screening is a highly effective method of identifying squamous cell cervical cancer, which is responsible for up to 90 of all cervical cancers. When identified early, cervical cancer can be treated and results in high 5 year survival rates of approximately 92. Pap tests are used to identify pre-cancerous or cancerous cells present on the cervix. When such cells are found, excision treatments can be used to completely remove the cancer. The detection of HPV DNA is used as an indication of the cancerous potential of a lesion and the potential risk of the woman developing cervical cancer in the future. According to the American Cancer Society (ACS) nearly all cases of cervical cancer test positive for HPV DNA. However, not all HPV types result in the development of cervical cancer. Two types of HPV, type 16 and type 18 have been found to be associated with 65 to 75 of all cervical cancers. Another 10 HPV types are associated with the remaining cases. The current recommendations from the Centers of Disease Control and Prevention (CDC), the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents state that for women with HIV infection, a Pap test should be obtained twice during the first year after diagnosis of HIV infection, even if younger than 21 years, and if the results are normal, annually thereafter (Kaplan, 2009). The combined guideline from the ACS, the American Society for Colposcopy and Cervical Pathology (ASCCP), and the American Society for Clinical Pathology (ASCP) (Saslow, 2012) regarding cervical cancer screening recommends against the use of cervical cancer screening in women under the age of 21. The ACS states the following: Cervical cancer is rare in adolescents and young women and may not be prevented by cytology screening. The incidence of cervical cancer screening in this age group has not changed with increasing screening coverage over the last 4 decades. Screening adolescents leads to unnecessary evaluation and potentially to the treatment of preinvasive cervical lesions that have a high probability of regressing spontaneously and that are on average many years from having significant potential for becoming invasive cancer. This overtreatment, and subsequent increased risk of reproductive problems, represents a net harm. The American College of Obstetricians and Gynecologists (ACOG) practice bulletin number 168, Screening for Cervical Cancer (2016), states that cervical cancer screening should begin at 21 years of age, with the exception of women who are infected with HIV or who are otherwise immunocompromised. Guidelines from the United States Preventive Services Task Force (USPSTF, 2018) currently recommend against cervical cancer screening for women There is data to indicate that women receiving immunosuppression following organ transplantation are at higher risk for invasive cancers. The U.S. Transplant Center Match (TCM) Study was a large population based cohort study using data from the U.S. Scientific Registry of Transplant Recipients (USSRTR) from 1987 to 2008 (Engels, 2011). A total of 175,732 subjects of any age with invasive cancers were included in the analysis. The authors reported that solid organ transplant recipients have an approximately 2-fold greater increase in risk of any type of cancer compared to the general public. While this study did not identify an increased risk of cervical cancer, the authors noted that this finding may be the result of a high rate of cervical cancer screening and rapid treatment of precancerous lesions. A follow-up investigation by Madeleine and others (2013) using USSRTR data reported on the incidence of HPV-related cancers in a cohort of 187,679 subjects with both invasive and in situ cancers and aged 18 years and older. In this study, risk data was presented in standardized incidence ratios (SIRs), which is a ratio of the observed incidence of a disease to the expected incidence of a disease in the general population. The reported SIR was 3.3 for in situ cervical cancer, and 1.0 for invasive cervical cancer. This indicated a greater than 3-fold increased risk of in situ cervical cancers and no increased risk for invasive cancers. However, it is clear that younger women who have received solid organ transplantation are at higher risk of cervical cancer, and that screening women in this population who are under the age of 21 should be considered. It is important to note that there are significant differences between general cancer screening and post-cancer diagnosis or treatment surveillance. The former is used to seek out new unidentified cancer cases in large portions of the general population with average risk of a disease. The latter is used to monitor the status of known disease (for example, someone with a greater than average risk for a disease) and minimize harms. These two uses are different clinically, and only screening is addressed in this document. The use of HPV testing has become widely used as a tool for the screening of individuals as risk of cervical cancer. However, the USPSTF (2012) has recommended “against screening for cervical cancer with HPV testing, alone or in combination with cytology, in women younger than age 30 years.” This position is supported by the ACS, ASCCP, and the ASCP (Saslow, 2012) by their recommendation that states HPV testing should not be used to screen women ages 21-29 years of age, either as a stand-alone test or as a cotest with cytology. They state that due to the high prevalence of HPV in women under the age of 30, the transient nature of these infections, and the low risk that such infections will develop into CIN3 or cancer, HPV testing should not be used to screen women in this age group. Their rationale further includes mention that the potential harms, such as increased unnecessary anxiety, discomfort and bleeding, and increased risk of pregnancy complications due to treatment, do not justify such testing. Cotesting should not be performed in women younger than 30 years.” For women 30 years and older, while cervical cytology is “acceptable,” ACOG states that HPV cotesting is “preferred” to cytology alone. Definitions Screening: The testing of persons, in either the general population or those at high risk, for specific diseases or conditions. Surveillance: The ongoing systematic active observation or testing of a medical condition with the purpose of detecting changes that warrant new or additional interventions to prevent and control its worsening or spreading. References Peer Reviewed Publications: Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011; 306(17):1891-1901. Madeleine MM, Finch JL, Lynch CF, et al. HPV-related cancers after solid organ transplantation in the United States. Am J Transplant. 2013; 13(12):3202-3209. Ogilvie GS, van Niekerk D, Krajden M, et al. Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial. JAMA. 2018; 320(1):43-52. Government Agency, Medical Society, and Other Authoritative Publications: American College of Obstetricians and Gynecologists. Practice Bulletin Number 168: Screening for Cervical Cancer. October, 2016. Kaplan JE, Benson C, Holmes, KK, et al. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR. 2009; 58(RR-4):1-207. Rockville, MD: Agency for Healthcare Research and Quality (US); 2018 Aug. Available at:. Accessed on November 1, 2019. Melnikow J, Henderson JT, Burda BU, et al. Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018; 320(7):687-705. Saslow D, Solomon D, Lawson HW, et al.; American Cancer Society; American Society for Colposcopy and Cervical Pathology; American Society for Clinical Pathology. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012; 137(4):516-542. US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, Barry MJ, et al. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018; 320(7):674-686. Index Cervical cancer The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available. Updated Discussion and References sections. Added “Using Cytology and” to title for clarification. Revised title. Added reference to ADMIN.00006 Preventive Health Guidelines to description section. Added MN and NMN statements regarding HPV testing. Updated Coding, Rationale and References section. Updated References section. Initial document development. The member's contract benefits in effect on the date that services are rendered must be used. Clinical UM Guidelines, which address medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Clinical UM Guidelines periodically. Clinical UM guidelines are used when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether or not to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the back of the member's card. Medicaid managed care administered by Amerigroup Partnership Plan, LLC, an independent company. This article has been cited by other articles in PMC. Abstract Cervical cancer is one of the most deadly and common forms of cancer among women if no action is taken to prevent it, yet it is preventable through a simple screening test, the so-called PAP-smear. This is the most effective cancer prevention measure developed so far. But the visual examination of the smears is time consuming and expensive and there have been numerous attempts at automating the analysis ever since the test was introduced more than 60 years ago. The first commercial systems for automated analysis of the cell samples appeared around the turn of the millennium but they have had limited impact on the screening costs. In this paper we examine the key issues that need to be addressed when an automated analysis system is developed and discuss how these challenges have been met over the years. The lessons learned may be useful in the efforts to create a cost-effective screening system that could make affordable screening for cervical cancer available for all women globally, thus preventing most of the quarter million annual unnecessary deaths still caused by this disease. 1. Cervical Cancer Screening Cancer of the cervix uteri is the second most common cancer among women worldwide, with more than half a million new cases each year and about half as many deaths. The variation in incidence rate between countries is striking. In many countries it is the most common cancer among women while in some countries it is down at 10th place. About 86 of the cases occur in developing countries. In Africa the age-standardized incidence rate is 25 per 100,000 per year; in some countries on that continent it is more than double that rate. While a part of this variation may be attributed to general variations in living conditions and the spread of the Human Papillomavirus, HPV, in the population the major part is attributed to the success of screening using the Papanicolaou test (PAP-test). The idea behind the PAP-test is that cellular changes that may develop into cancer are detected at such an early stage that they can be removed through a simple operation, thus preventing the cancer. Evidence for the importance of the PAP-test can be found in statistics from many countries where the PAP-test is used in systematic, comprehensive screening programs. In Sweden, for example, the overall incidence of cervical cancer declined by 67 over a 40-year period, from 20 cases per 100 000 in 1965 to 6.6 cases per 100 000 women in 2005. The cells are stained, fixated, and then visually examined under a microscope. The screening is conducted by cytotechnologists, cytotechs for short, who through a light microscope examine the cell sample for signs of malignancy. Through this procedure they can not only find proof of invasive cancer but also detect certain cancer precursors, allowing for early and effective treatment. The cytotechs are laboratory technologists who go through a specialized training, typically of about one year. When they find something that looks suspicious for malignancy on a specimen it is reported. In many labs the finding is then confirmed by a cytopathologist, a medical doctor specializing in cellular pathology, who makes the final decision whether it is a (pre-)malignant lesion or not and thus takes the medical responsibility for the diagnosis. A detected high grade premalignant lesion typically leads to the woman being offered a colposcopy and, if a lesion is confirmed, an operation to remove it. The detection of a low grade lesion may lead to a follow-up smear being taken after a shorter time interval than the normal 2-3 years. In principle, the screening task is straightforward. The morphological changes that a cell undergoes when it is being transformed into a malignant cell are quite apparent and easy to describe. Open in a separate window Figure 2 To the left a few normal cells and to the right some clearly atypical, premalignant cells. To visually detect these changes we need to see details close to the optical resolution limit. A nucleus is around 10 microns in diameter and the chromatin structures and shape variations are at the micron or submicron level. Therefore a high power lens is used, typically 40x. The precancerous lesion may be quite small and local and the number of diagnostic (pre-)malignant cells on a specimen may be low. It is desirable to detect a precancerous lesion even if there are only a few diagnostic cells present on the specimen. This creates a demanding search problem. The screening is initially done at low resolution using a 10x lens, and when something suspicious is seen the screener switches to 40x. At 10x around 1,000 fields of view need to be scrutinized to cover the whole sample. Even when following this recommendation, the cytotech has to inspect three image fields per second on the average. The hope was that an automated system would be able to do the screening both at a lower cost and with higher accuracy. Since then a large number of projects have attempted to develop screening systems. The problem turned out to be a lot harder than anticipated. It took more than 40 years before the first successful commercial systems appeared. And still automated screening is not sufficiently cost-effective to completely replace the visual screening judging from the relatively limited penetration of automated screening systems in the screening operations worldwide. In this section, we briefly outline this development and try to see for each new generation of systems in what ways they improved on earlier systems, what were the main problems, and what was learned. The system was based on the concept that cancer cells could be distinguished from normal cells on the basis of nuclear size and optical density. The system included automatic slide feed and autofocus circuits. The image analysis was based on hard-wired analogue video processing circuits that generated two-dimensional histograms of nuclear size versus nuclear optical density. The spatial resolution was 5 micrometers. Preliminary experiments had shown that it was possible to detect the difference in size between normal and malignant cells at this resolution. This was the first fully automated microscope and as such a quite expensive project. There were numerous objects of a size similar to malignant cells present also on normal specimens, for example, clumps of blood cells, strands of tissue and mucus, overlapping epithelial cells, and so forth. Every sample, including the normal ones, was thus found to be suspicious for abnormality. The project failed in the early sixties, mainly because of this artefact rejection problem. Due to the bad reputation for cytology automation caused by this early and expensive failure in the US, the attempts at automation over the next couple of decades were shifted to Europe and Japan. It failed for the same reason as the Cytoanalyzer. Their first version used special-purpose electronic circuits while later versions were based on general purpose digital computers, thus bridging the gap between old analogue and new digital technology. The pixel size was around one micron. They also realized that nuclear shape and chromatin pattern were useful parameters but were not able to reliably measure these features automatically mainly because the automatic focusing was unable to reliably produce images with all the cell nuclei in sufficiently good focus. The chromatin pattern measure that was proposed by this group was the number of blobs within the nuclear region. Four generations of prototype systems were developed over a 15-year period. The last one used strobed illumination and nonstop scanning motion to reach high scanning speeds. This, of course, made development much harder. However, during the seventies it became possible to develop interactive image analysis systems, albeit with very limited capacity, typically with a memory size of a few hundred kB and a monochrome or binary display. Typical cellular features used in these systems were similar to those used by CYBEST, although there were many variations in exactly how the features were extracted. The most important factor was found to be that the cells were digitized at sufficiently high resolution and in better focus. In order to be able to scan a whole specimen sufficiently rapidly while still being able to do the crucial analysis at high resolution, some of these designs, for example, the Diascanner, used a dual resolution approach, an initial low resolution search scan followed by high resolution scans of fields of interest. Most of these systems reached an operational prototype stage in the mideighties. Some of the systems reported classification accuracies that were well within the range of what is achieved by the conventional visual screening. But none reached the market, and an important reason for this was lack of cost effectiveness; automated microscopes and computers with sufficient processing power were still too expensive. The progress in computer display technology, that had been important in making it possible to create interactive systems that could be used for developing new automated screenings systems, eventually also led to the possibility of developing interactive screening systems. For the early systems the only option was full automation, or possibly stopping the automated microscope to physically show an operator the cell that was suspected as being abnormal. The concept was to create a “prescreening” system; that is, a system that for a reasonably large fraction of specimens would be able to say that they are perfectly normal and could be classified as such without any human inspection. All other specimens, on which the system found something that indicated that they might not be normal, would have to be screened in the conventional fully manual way. In the late eighties, computer displays and memories had reached sufficient capacity to make it feasible to save images of suspicious cells that were good enough for a human to judge whether the object could be a malignant cell or something else. After an initial low resolution object search, high resolution fields were processed, first by an algorithmic classifier and then by a neural network classifier.